Fig. 1 · Structure

Documents & Downloads

2-Methoxyestradiol

Cat. No. A10012 CAS 362-07-2

Apoptotic, antiproliferative and antiangiogenic agent

2-Methoxyestradiol is an apoptotic, antiproliferative and antiangiogenic agent. Induces p53-induced apoptosis via two pathways: activation of p38 and NF-κB; and activation of JNK and AP-1 leading to Bcl-2 phosphorylation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

2-Methoxyestradiol alters microtubule dynamics. In a purified-tubulin assay, 100 nM increased the fraction of growth time spent paused by approximately 61%; the authors reported no significant change in catastrophe rates. This experiment measures microtubule behavior, rather than a binding affinity or a selective HIF-inhibition constant. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HIF-2α (Rat aortic smooth muscle A-10 cells)
Microtubule Associated (Cell-free assay)
HIF-1α (MDA-MB-231 cells)

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 1.1 μM Antitumour activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay [PMID: 31102934]
B16 IC50 3.4 μM Antitumour activity against mouse B16 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay [PMID: 31102934]
Cancer cell lines GI50 0.7 μM Concentration required to inhibit the growth of HOP-6 human lung cancer cells by 50% [PMID: 16078843]
DU-145 GI50 1.2 μM Antiproliferative activity against human DU145 cells at 96 hrs by WST1 assay [PMID: 22247790]
DU-145 GI50 1.22 μM Antiproliferative activity against human DU145 cells after 96 hrs by WST-1 assay [PMID: 20225862]
DU-145 GI50 1.22 μM Antiproliferative activity against human DU145 cells after 96 hrs by WST1 assay [PMID: 17696419]
DU-145 GI50 1.8 μM Concentration required to inhibit the growth of DU-145 human prostate cancer cells by 50% [PMID: 16078843]
ECa-109 cell line IC50 4.1 μM Antitumour activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay [PMID: 31102934]
HCT-116 GI50 0.47 μM Antiproliferative activity against human HCT116 cells after 96 hrs by WST-1 assay [PMID: 20225862]
HCT-116 GI50 0.47 μM Concentration required to inhibit the growth of HCT116 human colon cancer cells by 50% [PMID: 16078843]
HEK-293T IC50 4.6 μM Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay [PMID: 36455509]
HeLa IC50 586 nM Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay [PMID: 20973488]
HeLa IC50 608 nM Antiproliferative activity against human HeLa cells by sulforhodamine B assay [PMID: 20973488]
HeLa IC50 8.6 μM Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay [PMID: 36455509]
HepG2 IC50 11.03 μM Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay [PMID: 28810190]
HepG2 IC50 2.3 μM Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay [PMID: 36455509]
HL-60 IC50 0.9 μM Cytotoxicity against vincristine-resistant human HL60 cells after 72 hrs MTS assay [PMID: 20411988]
HL-60 IC50 3.4 μM Cytotoxicity against human HL60 cells after 72 hrs MTS assay [PMID: 20411988]
HOP-62 GI50 0.7 μM Antiproliferative activity against human HOP62 cells after 96 hrs by WST-1 assay [PMID: 20225862]
HUVEC IC50 0.68 μM Antiangiogenic activity against HUVEC assessed as growth inhibition after 48 hrs by WST1 assay [PMID: 19782564]

20 records · Scroll to view more

2-Methoxyestradiol Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of 2-Methoxyestradiol from 3 published references. In vivo models include female Wistar rats, 155–165 g.

2-Methoxyestradiol In Vitro Studies

In primary female human pulmonary artery smooth muscle cells, 10 μmol/L 2-methoxyestradiol reduced proliferation and HIF1α/HK2 protein expression after 48 h. Related assays showed caspase-3/7 activation at 6 h and α-tubulin-network disruption at 24 h. Antagonists of ERα, ERβ or GPER did not reverse the antiproliferative response. Caspase 9 and p53 transcripts were reported unchanged. These findings are specific to the tested cells and exposures. [2]

Pausing of purified microtubule growth

Biochemical assay · Purified pig-brain tubulin growing from GMPCPP-stabilized microtubule seeds [1]

At 100 nM, 2-methoxyestradiol increased microtubule pausing in a cell-free assay. The main text reports no significant change in catastrophe rates.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fraction of total microtubule growth time spent pausedRelative increase versus control ~61%[1]
Total pause time within a microtubule growth eventDirection of change Increased[1]
Microtubule catastrophe rateOverall ANOVA p=0.22; no significant change reported[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
Reaction mixture preincubated 30 min at 37°C; subsequent imaging for 30 min at 30°C.
Method
12 μM tubulin reaction mixture; TIRF microscopy at 0.2 frames/s; growth pauses defined as growth rate <20 nm/s.
Vehicle
DMSO, with an equivalent-DMSO control.
Co-treatment
No co-treatment in the adopted 2-methoxyestradiol group; estradiol and colchicine were separate comparators.
Reported limits
Final DMSO percentage not specified in the relevant Methods. Figure 1C n values count analyzed growth events, not animals; Methods specifies at least 3 biological replicates per treatment group.
Methods and source locations

Compound reported in the paper: 2-Methoxyestradiol; Compound label in the paper: 2-ME; 2-Meth; Sigma-Aldrich M6383

Results apply to the reported compound, model and exposure; literature does not establish use or validation of Adooq material.

Results, first subsection; Figure 1B–C; Methods, Dynamic microtubule assay and TIRF microscopy / image analysis / Box plots

Fraction of total microtubule growth time spent paused: Kymograph analysis. Figure 1C: control N=54; 100 nM 2-Meth N=34. Overall three-group ANOVA p=1×10⁻5; not a pairwise 2-ME p value. Box: quartiles, median line, mean marker, min/max whiskers excluding outliers. — Results first subsection, paragraph beginning “We found”; Figure 1C right; Methods image analysis and Box plots

Total pause time within a microtubule growth event: Figure 1C left; overall three-group ANOVA p=8×10⁻6. Absolute bar/box values were not estimated. — Results first subsection; Figure 1B–C

Microtubule catastrophe rate: Result stated in the main narrative for control, estradiol and 2-ME; corresponding Supplementary Figure 1B image was not retrieved. — Results first subsection, paragraph beginning “Prior to pausing”; refers to Supplementary Figure 1B left

Proliferation, HIF-associated signaling and apoptosis in female hPASMCs

Cell-based study · Primary distal human pulmonary artery smooth muscle cells from female non-PAH donors [2]

2ME2 reduced proliferation and HIF1α/HK2 protein expression at 10 μmol/L. Related assays showed increased caspase-3/7 activity and disruption of the α-tubulin network; estrogen-receptor antagonists did not reverse the antiproliferative response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular proliferation and PCNA protein at 48 hDirection versus vehicle Reduced at 10 μmol/L[2]
Antiproliferative response during receptor-antagonist co-treatmentReversal test Not abrogated by MPP, PHTPP or G15[2]
HIF1α and HK2 protein after 48 h at 10 μmol/LDirection versus vehicle Reduced[2]
Bax/RIPK1 transcripts at 48 h and caspase-3/7 activity at 6 hDirection versus vehicle Increased[2]
Caspase 9 and p53 mRNA; BMPRII expressionReported null result No effect reported[2]
α-Tubulin organization and protein expression at 24 hDirection versus vehicle Network disrupted; protein expression reduced[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nmol/L–10 μmol/L for proliferation; 10 μmol/L for protein, transcript, apoptosis and microtubule assays.
Exposure duration
48 h for proliferation, PCNA, HIF1α, HK2 and transcript assays; 6 h for caspase-3/7; 24 h for Figure 6 α-tubulin assays.
Method
Serum-stimulated primary cell cultures; manual counts and CCK8, immunoblotting, qRT-PCR, CellEvent caspase-3/7 and immunofluorescence.
Co-treatment
Separate antagonist co-treatment groups: MPP, PHTPP or G15, each 100 nmol/L, with 10 μmol/L 2ME2. These are distinct from 2ME2-alone assays.
Reported limits
Vehicle composition and antagonist preincubation duration are not specified in the retrieved main text; expanded methods SI could not be retrieved. Figure 6 sample size is not specified in its caption. No graph-derived effect percentages or IC50 values are supplied.
Methods and source locations

Compound reported in the paper: 2-Methoxyestradiol; Compound label in the paper: 2ME2

Results apply to the reported compound, model and exposure; literature does not establish use or validation of Adooq material.

Methods, Cell Culture through Statistics; Results, cellular subsections; Figures 4–6; main-text discussion of Figure S3

Cellular proliferation and PCNA protein at 48 h: Manual cell counts and CCK8 (Figure 4A–B, n=4–5); PCNA immunoblot (4C, n=4–5). Mean±SEM. 4A–B ANOVA/Tukey; 4C paired t-test. Caption distinguishes these tests despite its broad A–D statement. — Results, Effects of 2ME2 on Cellular Proliferation in PASMCs; Figure 4A–C

Antiproliferative response during receptor-antagonist co-treatment: Separate groups, each antagonist 100 nmol/L with 2ME2 10 μmol/L; Figure 4D n=4, mean±SEM, ANOVA/Tukey. This is a model-specific antagonist result, not a receptor-binding selectivity measurement. — Results, Effects of 2ME2 on Cellular Proliferation in PASMCs; Figure 4D

HIF1α and HK2 protein after 48 h at 10 μmol/L: Immunoblotting; Figure 5A–B, n=4–5, mean±SEM; paired t-test. HIF1α *P<0.05, HK2 **P<0.01. No direct binding assay. — Results, Effect of 2ME2 on HIF1α Protein Expression in hPASMCs; Figure 5A–B

Bax/RIPK1 transcripts at 48 h and caspase-3/7 activity at 6 h: qRT-PCR at 10 μmol/L: n=4–5, paired t-tests; CellEvent caspase-3/7 at 10 μmol/L: n=3, ANOVA/Tukey; mean±SEM. — Results, Effects of 2ME2 on Expression of Proapoptotic and Antiproliferative Mediators; Figure 5C–E

Caspase 9 and p53 mRNA; BMPRII expression: Main Results text references Figure S3. SI images and detailed statistics were not retrieved, so no numerical null effect estimate is extracted. — Results, Effects of 2ME2 on Expression of Proapoptotic and Antiproliferative Mediators; final sentence referring to Figure S3

α-Tubulin organization and protein expression at 24 h: Human-cell immunofluorescence Figure 6C–D; immunoblot Figure 6E, mean±SEM, paired t-test *P<0.05. Figure caption specifies 10 μmol/L, 24 h. — Results, Effects of Microtubule Disrupters and 2ME2 on Cellular Morphology and Cytoskeletal Network in PASMCs; Figure 6C–E

2-Methoxyestradiol In Vivo Studies

In female Wistar rats given a single 10 mg kg−1 dose, plasma 2-methoxyestradiol was below the reported detection limit of 11 ng ml−1 after oral dosing and by 1 h after intravenous dosing. The authors could not determine parent-compound pharmacokinetic parameters from these data. [3]

In female nude mice bearing MDA-MB-435 melanoma xenografts, oral 2-methoxyestradiol at 20 mg kg−1 daily for 28 days did not significantly inhibit tumor growth during dosing or the subsequent 28-day observation period. Body-weight changes did not differ significantly from controls. This negative result is limited to that regimen and model. [3]

Single-dose plasma disposition in female rats

Animal study · Female Wistar rats, 155–165 g [3]

After a single 10 mg kg−1 dose, parent 2-MeOE2 was below the reported plasma detection limit after oral administration and by 1 h after intravenous administration. Parent-compound PK parameters could not be determined.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Parent plasma concentration 1 h after intravenous dosingBelow detection limit <11 ng ml−1[3]
Parent plasma detection after oral dosingBelow detection limit <11 ng ml−1[3]
Parent-compound pharmacokinetic parametersDetermination Could not be determined[3]

Conditions shared by the study groups

Frequency
Once
Vehicle
Propylene glycol:THF, 9:1 v v−1
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Parent 2-MeOE2, intravenous bolus
10 mg kg−1
Vehicle-only animals; bis-sulfamate tested as a separate comparator.Parent rapidly disappeared from plasma and was below 11 ng ml−1 by 1 h.[3]
Parent 2-MeOE2, oral
10 mg kg−1
Vehicle-only animals; bis-sulfamate tested as a separate comparator.Parent was not detected above the reported 11 ng ml−1 limit after oral dosing.[3]
Parent 2-MeOE2, intravenous bolus
Model: Female Wistar rats, 155–165 g
Route: Intravenous bolus
Treatment course: Single dose; blood sampling at 5, 15, 30 min and 1, 3, 8, 24 h.
Reported limits: Age and route-specific administration volume not specified in the retrieved Methods; n=3 in Figure 3 caption.
Parent 2-MeOE2, oral
Model: Female Wistar rats, 155–165 g
Route: Oral
Treatment course: Single dose; blood sampling at 15, 30 min and 1, 3, 8, 24, 48 h.
Reported limits: Age and route-specific administration volume not specified in the retrieved Methods; n=3 in Figure 3 caption.
Methods and source locations

Compound reported in the paper: 2-Methoxyestradiol; Compound label in the paper: 2-MeOE2; compound 1 in Figure 1

Results apply to the reported compound, model and exposure; literature does not establish use or validation of Adooq material.

Methods, In vivo pharmacokinetic and metabolism studies / HPLC analysis; Results, Pharmacokinetics of 2-MeOE2 and 2-MeOE2bisMATE; Figure 3

Parent plasma concentration 1 h after intravenous dosing: HPLC of extracted plasma; Results and Figure 3 specify the limit. Figure 3 means±s.e.m., n=3. No curve interpolation. — Results, Pharmacokinetics of 2-MeOE2 and 2-MeOE2bisMATE; Figure 3A and caption

Parent plasma detection after oral dosing: HPLC; oral sampling scheduled at 15 and 30 min and 1, 3, 8, 24 and 48 h. Figure 3 caption states oral parent levels were below LOD; n=3. — Methods, In vivo pharmacokinetic and metabolism studies; Results PK subsection; Figure 3 caption

Parent-compound pharmacokinetic parameters: Authors explicitly report insufficient detectable parent exposure for calculation; Table 1 belongs to 2-MeOE2bisMATE and is excluded. — Results, Pharmacokinetics of 2-MeOE2 and 2-MeOE2bisMATE, paragraph after Figure 3; Table 1 heading

Parent 2-MeOE2, intravenous bolus · Methods, In vivo pharmacokinetic and metabolism studies; Results PK subsection; Figure 3

Parent 2-MeOE2, oral · Methods, In vivo pharmacokinetic and metabolism studies; Results PK subsection; Figure 3

Oral treatment in MDA-MB-435 xenograft-bearing mice

Animal study · Female nude mice bearing MDA-MB-435 (ER−) human melanoma xenografts; n=8 per group [3]

Oral 2-MeOE2 at 20 mg kg−1 daily for 28 days did not significantly affect tumor growth during treatment or the following 28 days. Body-weight changes did not differ significantly from controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Xenograft volume during treatment and post-dosing follow-upComparison with vehicle control No significant effect[3]
Body-weight change during treatment and follow-upComparison with vehicle control No significant difference[3]

Conditions shared by the study groups

Route
Oral
Frequency
Daily
Treatment course
28 days of dosing followed by 28 days without dosing; tumor volume and weight measured weekly.
Vehicle
Dissolved in a minimum volume of THF, then diluted with propylene glycol.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Parent 2-MeOE2
20 mg kg−1
Vehicle (THF/propylene glycol). Separate bis-sulfamate comparator is not an adopted treatment arm.No significant tumor-growth effect during treatment or post-dosing; no significant difference in body-weight change.[3]
Parent 2-MeOE2
Model: Female nude mice; MDA-MB-435 (ER−) human melanoma xenografts; treatment initiated at 100–200 mm³
Reported limits: Mouse age and exact THF/propylene glycol ratio and administration volume not specified for this efficacy experiment. Do not borrow the rat PK formulation ratio.
Methods and source locations

Compound reported in the paper: 2-Methoxyestradiol; Compound label in the paper: 2-MeOE2; compound 1 in Figure 1

Results apply to the reported compound, model and exposure; literature does not establish use or validation of Adooq material.

Methods, In vivo inhibition of tumour growth / Statistics; Results, In vivo inhibition of tumour growth; Figures 4–5

Xenograft volume during treatment and post-dosing follow-up: Weekly tumor dimensions; volume calculated as l×w²/2; Figure 4 reports tumor volume relative to baseline, mean±s.e.m., n=8. Student’s t-test; exact parent-group P values not reported. — Methods, In vivo inhibition of tumour growth / Statistics; Results same subsection; Figure 4 and caption

Body-weight change during treatment and follow-up: Weekly weighing; Figure 5 mean±s.e.m., n=8. No numerical change estimated from the curve. — Results, In vivo inhibition of tumour growth, final sentence; Figure 5 and caption

Parent 2-MeOE2 · Methods, In vivo inhibition of tumour growth; Results same subsection; Figures 4–5

Specifications

Manufacturer Adooq Bioscience
CAS Number 362-07-2
Applications Apoptotic, antiproliferative and antiangiogenic agent
Formula C19H26O3
Molecular Weight 302.4
Synonyms 2-ME2
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C(OC)=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (181.87 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2%DMSO+30%PEG300+5%Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

2-Methoxyestradiol Research References

  1. [1] Ogren AN, Zimmerman NJ, Stark S, et al. Estradiol pauses microtubule growth without increased incidence of catastrophe events. Communications biology (2025). PMID: 40533494 DOI: 10.1038/s42003-025-08362-8 Source material
  2. [2] Docherty CK, Nilsen M, MacLean MR. Influence of 2-Methoxyestradiol and Sex on Hypoxia-Induced Pulmonary Hypertension and Hypoxia-Inducible Factor-1-α. Journal of the American Heart Association (2019). PMID: 30819028 DOI: 10.1161/jaha.118.011628 Source material
  3. [3] Ireson CR, Chander SK, Purohit A, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. British journal of cancer (2004). PMID: 14970876 DOI: 10.1038/sj.bjc.6601591 Source material

Added to your cart

View Cart Checkout
Loading...